Table 1.

Baseline patient characteristics (n=51)

Median age (range)	58 (19 – 79)
Female	21 (41.2%)
Stage III/IV	46 (90.2%)
Elevated LDH	17 (34.0%)
Median prior therapies (range)	2 (1 – 8)
Prior anthracycline	43 (84.3%)
Prior platinum	7 (13.7%)
Prior rituximab	29 (88%*)
Prior stem cell transplant	6 (11.8%)
Chemoresistant	28 (62.22%)**
Median tumor bulk, cm (range)	3.7 (1.2 – 13.5)

^*percent of CD20+ lymphomas,

^**based on n=45 with prior response data.